# Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

> **NCT02467270** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 283 (actual)

## Conditions studied

- Myeloid Leukemia, Chronic, Chronic Phase

## Interventions

- **DRUG:** Ponatinib

## Key facts

- **NCT ID:** NCT02467270
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-13
- **Primary completion:** 2020-04-29
- **Final completion:** 2025-04-23
- **Target enrollment:** 283 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02467270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02467270, "Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02467270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*